Positive Association of US-FLI With the Severity of CAD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

190 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-01

Study Completion Date

2025-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indicator (US-FLI) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. Our study aims to explore the relationship between US-FLI based on MAFLD and the severity of CHD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Quantitative US for Evaluation of Hepatic Steatosis in MAFLD With UDFF

NCT06097338

Fatty Liver Disease, Nonalcoholic

NOT_YET_RECRUITING

Ultrasound and Attenuation Imaging

NCT06552377

Non-Alcoholic Fatty Liver Disease Non Alcoholic Fatty Liver Non-alcoholic Steatohepatitis +1 more

COMPLETED

A Clinical Study of Ultrasound-derived Fat Fraction to Assess Metabolic Dysfunction-Associated Steatotic Liver Disease

NCT06487325

Fatty Liver Disease

COMPLETED

Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter

NCT06203548

Fatty Liver

RECRUITING NA

Radiological Spectrum Of Fatty Liver Correlate With High Resolution Ultrasonography Of Fibrosis And Cirrhosis

NCT06749522

Fibrosis Cirrhosis

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

204 patients who had invasive coronary angiography performed between July 2022 and December 2023 at the cardiology department of the Second Affiliated Hospital of Chongqing Medical University were included in this study. Collect clinical information and abdominal ultrasound images from each patient. Hepatic steatosis which quantified by US-FLI was evaluated by the echo contrast between liver and kidney, posterior attenuation of ultrasound beam, areas of focal sparing, display of hepatic vessels, gallbladder wall and diaphragm. Fatty liver was diagnosed when US-FLI≥2. The severity of CHD was evaluated using the SYNTAX score (SS), and a total of 100 CHD patients were ultimately diagnosed. CHD patients were further divided into the low-risk group (SS ≤ 22) (54 cases) and the medium-high-risk group (SS≥23) (46 cases). Multivariate logistic regression model was used to assess the relationship between US-FLI and SS in patients with MAFLD. The receiver operating characteristic curve was used to determine the accuracy, sensitivity and specificity of US-FLI in predicting SS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease of Significant Bypass Graft Metabolic Dysfunction-associated Fatty Liver Disease SYNTAX Score Ultrasonography

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-CAD group

non-coronary artery disease group

No interventions assigned to this group

CAD group

coronary artery disease group

Observational study without human intervention

Intervention Type OTHER

Observational study without human intervention

SS≤22 group

SYNTAX score ≤22

No interventions assigned to this group

SS≥23 group

SYNTAX score ≥23

Observational study without human intervention

Intervention Type OTHER

Observational study without human intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational study without human intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients older than 18 years old
* Patients underwent ICA due to chest pain, chest tightness or other reasons in our hospital from August 2022 to December 2023 were included in our study

Exclusion Criteria

* Incomplete clinical data
* previous coronary stent implantation
* no abdominal ultrasound examination
* poor ultrasound image quality
* congenital heart disease
* tumor
* thyroid diseases and infectious diseases

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes